NCT01050582 – Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Posted on December 20, 2018 by tsuperadmin -
NCT00576732 – Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety Posted on December 20, 2018 by tsuperadmin -
NCT00236379 – A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Posted on December 20, 2018 by tsuperadmin -
NCT00216632 – Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) Posted on December 20, 2018 by tsuperadmin -
NCT00369239 – Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta? Posted on December 20, 2018 by tsuperadmin -
NCT00216671 – Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode Posted on December 20, 2018 by tsuperadmin -
NCT00249223 – Risperidone Depot (Microspheres) vs. Risperidone Tablets – a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia Posted on March 8, 2018 by tsuperadmin -
NCT00044681 – A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression Posted on August 24, 2017 by tsuperadmin -
NCT00246246 – A Randomized, Open-label Trial of RISPERDAL® CONSTA™ Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder Posted on November 2, 2016 by tsuperadmin -
An open-label, long-term study of risperidone for the treatment of behavioral disturbances in patients with dementia Posted on May 9, 2016 by tsuperadmin -
The YODA Project